Research Advances on the Stability of mRNA Vaccines
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Compared to other vaccines, the inherent properties of messenger RNA (mRNA) vaccines and their interaction with lipid nanoparticles make them considerably unstable throughout their life cycles, impacting their effectiveness and global accessibility. It is imperative to improve mRNA vaccine stability and investigate the factors influencing stability. Since mRNA structure, excipients, lipid nanoparticle (LNP) delivery systems, and manufacturing processes are the primary factors affecting mRNA vaccine stability, optimizing mRNA structure and screening excipients can effectively improve mRNA vaccine stability. Moreover, improving manufacturing processes could also prepare thermally stable mRNA vaccines with safety and efficacy. Here, we review the regulatory guidance associated with mRNA vaccine stability, summarize key factors affecting mRNA vaccine stability, and propose a possible research path to improve mRNA vaccine stability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · cited 1×
“[21] described the injection of naked mRNA”
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801 · cited 1×
“In the treatment of genetic diseases, clinical trials are ongoing for mRNA vaccines for cystic fibrosis [25], propionic acidemia [26], and transthyretin amyloidosis [27].”
BackgroundFreeze-drying of nanoparticles: Formulation, process and storage considerations
ABDELWAHED, W., DEGOBERT, G., STAINMESSE, S., & FESSI, H. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.017 · Cited by 1,611 · cited 1×
“The most popular cryoprotectants reported in the literature for freeze-drying nanoparticles include trehalose, sucrose, glucose and mannitol [104].”
BackgroundmRNA-lipid nanoparticle COVID-19 vaccines: structure and stability
Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120586 · Cited by 1,566
Codon bias and heterologous protein expression
Gustafsson, C., Govindarajan, S., & Minshull, J. (2004) · Trends in Biotechnology · doi:10.1016/j.tibtech.2004.04.006 · Cited by 1,330 · cited 1×
“Replacing rare codons with common codons increases mRNA translation [44].”
BackgroundLipid Nanoparticle Systems for Enabling Gene Therapies
Cullis, P. R., & Hope, M. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.013 · Cited by 1,208
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127 · cited 2×
“Additionally, this property of ionizable lipids can be exploited to help LNPs escape from the endosomes [80,87].”
BackgroundDuan, X., & Li, Y. (2013) · Small · doi:10.1002/smll.201201390 · Cited by 926
Cationic liposome-mediated RNA transfection.
Malone, R. W., Felgner, P. L., & Verma, I. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.16.6077 · Cited by 911
Engineering circular RNA for potent and stable translation in eukaryotic cells
Wesselhoeft, R. A., Kowalski, P. S., & Anderson, D. G. (2018) · Nature Communications · doi:10.1038/s41467-018-05096-6 · Cited by 853 · cited 1×
“circRNA can be expressed consistently in cells for 5 to 7 days, whereas linear mRNA with the same sequence is reportedly only consistently expressed for 2 days [66,67].”
BackgroundSabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.010 · Cited by 820 · cited 1×
“mRNAs can be protected by LNPs from ribonuclease degradation and enter cells by endocytosis then escape into the cytoplasm via endosomes to complete mRNA translation and expression [76].”
BackgroundTools for translation: non-viral materials for therapeutic mRNA delivery
Hajj, K. A., & Whitehead, K. A. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.56 · Cited by 799 · cited 1×
“Cholesterol enhances particle stability by modulating membrane integrity and rigidity [80,81].”
BackgroundAlameh, M.-G., Tombácz, I., Bettini, E., Lederer, K., Ndeupen, S., Sittplangkoon, C., Wilmore, J. R., Gaudette, B. T., Soliman, O. Y., Pine, M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.001 · Cited by 775
Enuka, Y., Lauriola, M., Feldman, M. E., Sas-Chen, A., Ulitsky, I., & Yarden, Y. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1367 · Cited by 757
Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.051 · Cited by 701 · cited 1×
“m1ψTP has a better safety profile and more effectively reduces immune stimulation compared to pseudouridine [57].”
BackgroundA thermostable mRNA vaccine against COVID-19
Zhang, N.-N., Li, X.-F., Deng, Y.-Q., Zhao, H., Huang, Y.-J., Yang, G., Huang, W.-J., Gao, P., Zhou, C., Zhang, R.-R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.024 · Cited by 694 · cited 4×
“developed a novel liquid formulation of a COVID-19 mRNA vaccine based on LNP-encapsulated mRNA that encodes the RBD sequence of SARS-CoV-2 [112].”
BackgroundInfluentialSelf-citationCircular RNA Vaccines against SARS-CoV-2 and Emerging Variants
Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., Wu, Z., Tang, H., Zhang, X., Tian, F., et al. (2021) · doi:10.1101/2021.03.16.435594 · Cited by 636 · cited 1×
“[68] using LNPs was also significantly better than that of linear mRNA vaccines at 4, 25, and 37 ◦C.”
Self-citationHoltkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625 · cited 2×
“In addition, the length of the poly A tail affects translation efficiency and protein expression levels [52,54].”
BackgroundPatel, S., Ashwanikumar, N., Robinson, E., Xia, Y., Mihai, C., Griffith, J. P., Hou, S., Esposito, A. A., Ketova, T., Welsher, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14527-2 · Cited by 601 · cited 1×
“The molecular geometry of cholesterol derivatives can further affect the delivery efficiency and biodistribution of LNPs [82].”
BackgroundThess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P., Fotin-Mleczek, M., & Schlake, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.103 · Cited by 556
mRNA structure regulates protein expression through changes in functional half-life
Mauger, D. M., Cabral, B. J., Presnyak, V., Su, S. V., Reid, D. W., Goodman, B., Link, K., Khatwani, N., Reynders, J., Moore, M. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908052116 · Cited by 555
High Guanine and Cytosine Content Increases mRNA Levels in Mammalian Cells
Kudla, G., Lipinski, L., Caffin, F., Helwak, A., & Zylicz, M. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040180 · Cited by 476
McKay, P. F., Hu, K., Blakney, A. K., Samnuan, K., Brown, J. C., Penn, R., Zhou, J., Bouton, C. R., Rogers, P., Polra, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17409-9 · Cited by 462 · cited 1×
“The major advantage of saRNA is that it can achieve protein expression levels similar to those of conventional mRNA at low doses [69,70].”
BackgroundFeldman, R. A., Fuhr, R., Smolenov, I., (Mick) Ribeiro, A., Panther, L., Watson, M., Senn, J. J., Smith, M., Almarsson, Ӧ., Pujar, H. S., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.074 · Cited by 454 · cited 1×
“mRNA vaccines are currently undergoing clinical trials for the prevention and control of diseases other than COVID-19 vaccines, including vaccines for influenza [24], human immunodeficiency virus (NCT05001373), Zika virus (NCT04064905), respiratory syncytial virus (NCT04528719), and cytomegalovirus (NCT04232280).”
BackgroundmRNA therapeutics in cancer immunotherapy
Beck, J. D., Reidenbach, D., Salomon, N., Sahin, U., Türeci, Ö., Vormehr, M., & Kranz, L. M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01348-0 · Cited by 385 · cited 1×
“Messenger RNA (mRNA) serves as a template for protein translation [1].”
BackgroundChallenges of Storage and Stability of mRNA-Based COVID-19 Vaccines
Uddin, M. N., & Roni, M. A. (2021) · Vaccines · doi:10.3390/vaccines9091033 · Cited by 371 · cited 1×
“Due to the instability of mRNA, the vaccine produced by Pfizer needs to be kept below −70 degrees Celsius, while Moderna’s vaccine only needs to be kept below −20 degrees Celsius, which has restricted access to effective immunization for populations in underdeveloped countries and resulted in the discarding of a large…”
BackgroundAnderson, B. R., Muramatsu, H., Jha, B. K., Silverman, R. H., Weissman, D., & Kariko, K. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr586 · Cited by 356 · cited 1×
“Sequence modifications reduce the inflammationstimulating effects of mRNA and cleavage by nucleases, improve mRNA stability, and enhance translation levels [22,56].”
BackgroundBall, R., Bajaj, P., & Whitehead, K. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s123062 · Cited by 333 · cited 4×
“It has a shelf life of 3 years at 2–8 ◦C with no significant changes in the indicators during storage [35,43].”
BackgroundInfluentialMuramatsu, H., Lam, K., Bajusz, C., Laczkó, D., Karikó, K., Schreiner, P., Martin, A., Lutwyche, P., Heyes, J., & Pardi, N. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.001 · Cited by 331
Theoretical basis for stabilizing messenger RNA through secondary structure design
Wayment-Steele, H. K., Kim, D. S., Choe, C. A., Nicol, J. J., Wellington-Oguri, R., Watkins, A. M., Sperberg, R. A. P., Huang, P.-S., Participants, E., & Das, R. (2020) · doi:10.1101/2020.08.22.262931 · Cited by 199
Theoretical basis for stabilizing messenger RNA through secondary structure design
Wayment-Steele, H. K., Kim, D. S., Choe, C. A., Nicol, J. J., Wellington-Oguri, R., Watkins, A. M., Parra Sperberg, R. A., Huang, P.-S., Participants, E., & Das, R. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab764 · Cited by 197
The effects of PEGylation on LNP based mRNA delivery to the eye
Ryals, R. C., Patel, S., Acosta, C., McKinney, M., Pennesi, M. E., & Sahay, G. (2020) · PLOS ONE · doi:10.1371/journal.pone.0241006 · Cited by 194
de Alwis, R., Gan, E. S., Chen, S., Leong, Y. S., Tan, H. C., Zhang, S. L., Yau, C., Low, J. G. H., Kalimuddin, S., Matsuda, D., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.001 · Cited by 191
Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency
Prieve, M. G., Harvie, P., Monahan, S. D., Roy, D., Li, A. G., Blevins, T. L., Paschal, A. E., Waldheim, M., Bell, E. C., Galperin, A., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.024 · Cited by 145
Nanomedicine-Based Approaches for mRNA Delivery
Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139
Nanoplatforms for mRNA Therapeutics
Meng, C., Chen, Z., Li, G., Welte, T., & Shen, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000099 · Cited by 130 · cited 3×
“Additionally, this property of ionizable lipids can be exploited to help LNPs escape from the endosomes [80,87].”
BackgroundLong-term storage of DNA-free RNA for use in vaccine studies
Jones, K. L., Drane, D., & Gowans, E. J. (2007) · BioTechniques · doi:10.2144/000112593 · Cited by 115 · cited 1×
“reported that mRNA lyophilized with 10% trehalose as a protectant had high translation and protein expression levels even after storage for 10 months at 4 ◦C [107].”
BackgroundGC content around splice sites affects splicing through pre-mRNA secondary structures
Zhang, J., Kuo, C. J., & Chen, L. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-90 · Cited by 108
pEVL: A Linear Plasmid for Generating mRNA IVT Templates With Extended Encoded Poly(A) Sequences
Grier, A. E., Burleigh, S., Sahni, J., Clough, C. A., Cardot, V., Choe, D. C., Krutein, M. C., Rawlings, D. J., Jensen, M. C., Scharenberg, A. M., et al. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.21 · Cited by 95
Karikó, K., Kuo, A., & Barnathan, E. S. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300930 · Cited by 89
Improved translation efficiency of therapeutic mRNA
Zarghampoor, F., Azarpira, N., Khatami, S. R., Behzad-Behbahani, A., & Foroughmand, A. M. (2019) · Gene · doi:10.1016/j.gene.2019.05.008 · Cited by 72 · cited 1×
“Concerning the optimization of mRNA UTRs, the introduction of the Kozak consensus sequence after the 5′ UTR can also improve the stability and translation initiation level [49].”
MethodsiRNA-lipid nanoparticles with long-term storage stability facilitate potent gene-silencing in vivo
Suzuki, Y., Hyodo, K., Tanaka, Y., & Ishihara, H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.024 · Cited by 71 · cited 1×
“It has a shelf life of 3 years at 2–8 ◦C with no significant changes in the indicators during storage [35,43].”
BackgroundKaukinen, U. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.2.468 · Cited by 69 · cited 1×
“Similarly, mRNA hydrolysis is affected by base sequence [30] and mRNA secondary structure [31,32].”
BackgroundThe effect of secondary structure on cleavage of the phosphodiester bonds of RNA
Mikkola, S., Kaukinen, U., & Lönnberg, H. (2001) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:34:1:95 · Cited by 67 · cited 1×
“Similarly, mRNA hydrolysis is affected by base sequence [30] and mRNA secondary structure [31,32].”
BackgroundZhao, H., Wang, T.-C., Li, X.-F., Zhang, N.-N., Li, L., Zhou, C., Deng, Y.-Q., Cao, T.-S., Yang, G., Li, R.-T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00861-4 · Cited by 60
Ayat, N. R., Sun, Z., Sun, D., Yin, M., Hall, R. C., Vaidya, A. M., Liu, X., Schilb, A. L., Scheidt, J. H., & Lu, Z.-R. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0784 · Cited by 33
Metadata
- Authors
- Cheng, F., Wang, Y., Bai, Y., Liang, Z., Mao, Q., Liu, D., Wu, X., & Xu, M.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2023-03-02
- Volume
- 15
- Issue
- 3
- Pages
- 668
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W4322770550
- Cited by
- 162
- References
- 48
- FWCI
- 12.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.